Il-7rα low memory cd8 + t cells are significantly elevated in patients with systemic lupus erythematosus

Rheumatology (United Kingdom)

Volumn 51, Issue 9, 2012, Pages 1587-1594

  Kim, Jung Sik ^a   Cho, Bon A ^a   Sim, Ji Hyun ^a   Shah, Kamini ^b   Woo, Connie M ^b   Lee, Eun Bong ^a   Lee, Dong Sup ^a   Kang, Jae Seung ^a   Lee, Wang Jae ^a   Park, Chung Gyu ^a   Craft, Joe ^b   Kang, Insoo ^b   Kim, Hang Rae ^a  

^a Seoul National University College of Medicine   (South Korea)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2B4; Cytolytic function; Human CD8+ T cells; IL 7 receptor alpha ( ) chain; NK receptor; Systemic lupus erythematosus

Indexed keywords

CD48 ANTIGEN; INTERLEUKIN 7 RECEPTOR ALPHA;

ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; MEMORY CELL; NATURAL KILLER CELL; PATHOGENESIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, BLOCKING; ANTIGENS, CD; CD8-POSITIVE T-LYMPHOCYTES; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE COUNT; RECEPTORS, IMMUNOLOGIC; RECEPTORS, INTERLEUKIN-7;

EID: 84865318336     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes100     Document Type: Article

References (40)

1. Gray D, Matzinger P. T cell memory is short-lived in the absence of antigen. J Exp Med 1991;174:969-74.
2. Tan JT, Ernst B, Kieper WC et al. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med 2002;195: 1523-32.
3. Kim HR, Hwang KA, Park SH, Kang I. IL-7 and IL-15: biology and roles in T-cell immunity in health and disease. Crit Rev Immunol 2008;28:325-39.
4. Kim HR, Hong MS, Dan JM, Kang I. Altered IL-7Ralpha expression with aging and the potential implications of IL-7 therapy on CD8+ T-cell immune responses. Blood 2006;107:2855-62.
5. Boutboul F, Puthier D, Appay V et al. Modulation of interleukin-7 receptor expression characterizes differentiation of CD8 T cells specific for HIV, EBV and CMV. AIDS 2005;19:1981-6.
6. Paiardini M, Cervasi B, Albrecht H et al. Loss of CD127 expression defines an expansion of effector CD8+ T cells in HIV-infected individuals. J Immunol 2005;174: 2900-9.
7. Radziewicz H, Ibegbu CC, Hon H et al. Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection. J Virol 2008;82:9808-22.
8. Zhang SY, Zhang Z, Fu JL et al. Progressive CD127 down-regulation correlates with increased apoptosis of CD8 T cells during chronic HIV-1 infection. Eur J Immunol 2009;39:1425-34.
9. Herrmann M, Voll RE, Kalden JR. Etiopathogenesis of systemic lupus erythematosus. Immunol Today 2000;21: 424-6.
10. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001;1:147-53.
11. Vratsanos GS, Jung S, Park YM, Craft J. CD4(+) T cells from lupus-prone mice are hyperresponsive to T cell receptor engagement with low and high affinity peptide antigens: a model to explain spontaneous T cell activation in lupus. J Exp Med 2001;193:329-37.
12. Blanco P, Pitard V, Viallard JF et al. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2005;52:201-11.
13. Fritsch RD, Shen X, Illei GG et al. Abnormal differentiation of memory T cells in systemic lupus erythematosus. Arthritis Rheum 2006;54:2184-97.
14. Couzi L, Merville P, Deminiere C et al. Predominance of CD8+ T lymphocytes among periglomerular infiltrating cells and link to the prognosis of class III and class IV lupus nephritis. Arthritis Rheum 2007;56:2362-70.
15. Endt J, Eissmann P, Hoffmann SC et al. Modulation of 2B4 (CD244) activity and regulated SAP expression in human NK cells. Eur J Immunol 2007;37:193-8.
16. Brown MH, Boles K, van der Merwe PA et al. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J Exp Med 1998;188: 2083-90.
17. Chuang SS, Kim MH, Johnson LA et al. 2B4 stimulation of YT cells induces natural killer cell cytolytic function and invasiveness. Immunology 2000;100:378-83.
18. Messmer B, Eissmann P, Stark S, Watzl C. CD48 stimulation by 2B4 (CD244)-expressing targets activates human NK cells. J Immunol 2006;176:4646-50.
19. Lee KM, Bhawan S, Majima T et al. Cutting edge: the NK cell receptor 2B4 augments antigen-specific T cell cytotoxicity through CD48 ligation on neighboring T cells. J Immunol 2003;170:4881-5.
20. Valiante NM, Trinchieri G. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes. J Exp Med 1993;178:1397-406.
21. Sivori S, Parolini S, Falco M et al. 2B4 functions as a co-receptor in human NK cell activation. Eur J Immunol 2000;30:787-93.
22. Johnson LA, Goldfarb RH, Mathew PA. Regulation of IFN-gamma production following 2B4 activation in human NK cells. In Vivo 2000;14:625-9.
23. Speiser DE, Colonna M, Ayyoub M et al. The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alpha beta T cells. J Immunol 2001;167:6165-70.
24. Dupre L, Andolfi G, Tangye SG et al. SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells. Blood 2005;105:4383-9.
25. Enose-Akahata Y, Matsuura E, Oh U, Jacobson S. High expression of CD244 and SAP regulated CD8 T cell responses of patients with HTLV-I associated neurologic disease. PLoS Pathog 2009;5:e1000682.
26. Lee KM, McNerney ME, Stepp SE et al. 2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. J Exp Med 2004; 199:1245-54.
27. Vacca P, Pietra G, Falco M et al. Analysis of natural killer cells isolated from human decidua: evidence that 2B4 (CD244) functions as an inhibitory receptor and blocks NK-cell function. Blood 2006;108:4078-85.
28. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
29. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004;294:15-22.
30. Franceschetti M, Pievani A, Borleri G et al. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol 2009;37:616-28.e2.
31. Kim HR, Hwang KA, Kang I. Dual roles of IL-15 in maintaining IL-7RalphalowCCR7-memory CD8+ T cells in humans via recovering the phosphatidylinositol 3-kinase/ AKT pathway. J Immunol 2007;179:6734-40.
32. Maasho K, Opoku-Anane J, Marusina AI, Coligan JE, Borrego F. NKG2D is a costimulatory receptor for human naive CD8+ T cells. J Immunol 2005;174: 4480-4.
33. Warren HS, Rana PM, Rieger DT et al. CD8 T cells expressing killer Ig-like receptors and NKG2A are present in cord blood and express a more naive phenotype than their counterparts in adult blood. J Leukoc Biol 2006;79: 1252-9.
34. Henson SM, Franzese O, Macaulay R et al. KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells. Blood 2009;113:6619-28.
35. Peritt D, Sesok-Pizzini DA, Schretzenmair R et al. C1.7 antigen expression on CD8+ T cells is activation dependent: increased proportion of C1.7+CD8+ T cells in HIV-1-infected patients with progressing disease. J Immunol 1999;162:7563-8.
36. Pinkse GG, Tysma OH, Bergen CA et al. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci USA 2005;102:18425-30.
37. Blanco P, Viallard JF, Pellegrin JL, Moreau JF. Cytotoxic T lymphocytes and autoimmunity. Curr Opin Rheumatol 2005;17:731-4.
38. Mozes E, Kohn LD, Hakim F, Singer DS. Resistance of MHC class I-deficient mice to experimental systemic lupus erythematosus. Science 1993;261:91-3.
39. Chen SY, Takeoka Y, Pike-Nobile L et al. Autoantibody production and cytokine profiles of MHC class I (beta2-microglobulin) gene deleted New Zealand black (NZB) mice. Clin Immunol Immunopathol 1997;84: 318-27.
40. Reynolds J, Norgan VA, Bhambra U et al. Anti-CD8 monoclonal antibody therapy is effective in the prevention and treatment of experimental autoimmune glomerulonephritis. J Am Soc Nephrol 2002;13:359-69.